Osteopore International wins Made in Singapore – Medical award

Once its 3D-printed bone graft biodegrades, it leaves behind viable new bone in its place.

Medical technology firm Osteopore International has bagged the Made in Singapore – Medical trophy for its Osteomesh for Orthopaedic device at the recently concluded Made in Singapore and Designed in Singapore awards presented by Singapore Business Review.

Now in its fourth year, the awards event lauds manufacture and product design excellence in various industries.

Osteomesh for Orthopaedic is a structured bone graft that is shaped to fill the void created in trauma cases in the extremities such as the shin bone or radius bone. Its unique architecture allows for rapid saturation with marrow, blood and nutrients, thus providing the patient’s own cells with chemical signals that are required for bone growth and remodeling.

The device is 3D printed with porosity to facilitate bone tissue and micro-blood vessels integration.

The mesh offers a rigid yet flexible scaffold with sufficient mechanical strength that supports bone in-growth. As the new material will biodegrade over a period of 18-24 months, it will leave behind viable new bone in its place.

Ten successful cases have been conducted in Singapore, Germany, Oman and Australia using Osteomesh, varying from eight years to six months post operatively.

The first human case of a 36cm tibia reconstruction took place in 2017. Two years post surgery, the patient was able to walk with support and the Osteomesh device was observed to have biodegraded.

Osteopore specialises in the production of 3D printed bioresorbable implants used in conjunction with surgical procedures to assist with natural stages of bone healing. The company was founded in November 2003 in a bid to commercialise 3D printed scaffold technology to aid the adoption of tissue engineering and regenerative medicine in clinical treatment.

Osteopore’s other product is the Osteoplug, a bioresorbable implant used for covering trephination burr holes and other cranial defects in neurosurgery. Long-term clinical trials showed significant bone regeneration, re-covering the burr hole as the material is resorbed by the body and replaced by autologous bone.

The firm’s products are made of a biocompatible polymer called polycaprolactone (PCL), which is bioresorbable, malleable, slow-degrading and possesses mechanical strength to trabecular bone.

According to the World Intellectual Property Organisation (WIPO), Osteopore is at the forefront of research and development (R&D) within the tissue engineering industry, having reached a market size of US$90b in 2010.

“Repairing skull fractures has traditionally been an expensive, painful process filled with unwanted side effects. Osteopore’s innovative technology significantly mitigates these risks, and provides the healthcare industry with a better and safer way to care for patients,” WIPO said.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia